// App-Quantinova.ai

1900 : Premedication and Longer Infusion Time Do Not Reduce the Incidence of Hypersensitivity Reactions to Pegaspargase

Researchers

Presenter

  • Catherine Hughes

Principal Investigators

  • Valeria Bernardo

  • Susanne Youssef

  • James P. Hughes

  • Frank G. Keller

  • Tamara P. Miller

  • Sharon M. Castellino

  • Glen Lew

Medical Centers

  • Emory University, Aflac Cancer and Blood Disorders Center, Childrens Healthcare of Atlanta, Atlanta, GA

  • University of Washington School of Medicine, Seattle, WA

  • Aflac Cancer and Blood Disorders Center, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA

  • Aflac Cancer and Blood Disorders Center, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA

  • Aflac Cancer and Blood Disorders Center, Emory Univ. / Children's Healthcare of Atlanta, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Erwinase

  • Diphenhydramine

  • Derma-Pax lotion

  • Hydrocortisone

  • Pegaspargase

  • Oncaspar

  • Asparaginase

  • Ranitidine

  • Famotidine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved